Friday, October 26, 2007

Allozyne Raises $30M

Seattle-based Allozyne said Friday that it has closed on $30M in Series B funding for the firm's biotechnology products. The funding came from MPM Capital, and also included OVP Venture Partners, Amgen Ventures, ARCH Venture Partners, and Alexandria Real estate Equities. The funding will go towards the company's lead product candidate, which is a version of Interferon beta for the treatment of Multiple Sclerosis (MS). Allozyne said the investment follows a Series A in November of 2005 from the Accelerator Corporation. More information »